Short answer · Medically reviewed summary · Last updated: 2026-05-08
Adrenal Cortical Carcinoma (ACC) is a rare malignancy, with an estimated annual incidence of 0.7 to 2 cases per million people worldwide. While the exact prevalence is difficult to determine due to the disease's aggressive nature and high mortality, it remains a rare condition that requires specialized oncological care. Is Adrenal Cortical Carcinoma (ACC) considered rare? Yes, Adrenal Cortical Carcinoma (ACC) is classified as a rare disease.
What is the prevalence of Adrenal Cortical Carcinoma (ACC)?
Prevalence of Adrenal Cortical Carcinoma (ACC): how many people are affected worldwide, differences by sex and region, with sources.
Adrenal Cortical Carcinoma (ACC) is a rare malignancy, with an estimated annual incidence of 0.7 to 2 cases per million people worldwide. While the exact prevalence is difficult to determine due to the disease's aggressive nature and high mortality, it remains a rare condition that requires specialized oncological care.
Is Adrenal Cortical Carcinoma (ACC) considered rare?
Yes, Adrenal Cortical Carcinoma (ACC) is classified as a rare disease. Because it is so uncommon, many physicians may only encounter one or two cases in their entire career. At DiseaseMaps.org, 265 people with Adrenal Cortical Carcinoma (ACC) have joined our community, providing a vital real-world perspective on living with this diagnosis that often exceeds the data found in standard clinical registries.
What are the incidence and demographic patterns of ACC?
The incidence of Adrenal Cortical Carcinoma (ACC) is approximately 1 per million population annually, according to NIH GARD. Epidemiological data indicates several distinct patterns:
- Gender Distribution: ACC shows a slight female predominance, with a female-to-male ratio of approximately 1.5:1.
- Age of Onset: The condition exhibits a bimodal age distribution, with peaks in early childhood (under age 5) and in adults between the ages of 40 and 50.
- Geographic Variation: Notably higher incidences of Adrenal Cortical Carcinoma (ACC) have been observed in southern Brazil, linked to a specific germline mutation in the TP53 gene.
Why is accurate prevalence data for ACC challenging?
Estimating the true prevalence of Adrenal Cortical Carcinoma (ACC) is hindered by several factors. Underdiagnosis is common because early-stage tumors may be asymptomatic or misidentified as benign adrenal adenomas. Furthermore, because Adrenal Cortical Carcinoma (ACC) is highly aggressive, the time between diagnosis and mortality can be short, which complicates point-prevalence counts in clinical databases.
Next steps
- Consult with an endocrinologist or medical oncologist specializing in adrenal malignancies.
- Seek genetic counseling to evaluate for hereditary cancer syndromes, such as Li-Fraumeni syndrome.
- Join the DiseaseMaps.org community to connect with other families navigating Adrenal Cortical Carcinoma (ACC).
- Inquire about clinical trials through the National Cancer Institute (NCI) for the latest treatment protocols.
Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Adrenocortical carcinoma.
- Orphanet: Adrenocortical carcinoma (ORPHA:187).
- National Cancer Institute (NCI): Adrenocortical Carcinoma Treatment (PDQ®)–Patient Version.
- American Cancer Society: Key Statistics for Adrenal Cortical Carcinoma.
